| 1. |
- Ejjeh, Adel, et al.
(författare)
-
HPVM2FPGA: Enabling True Hardware-Agnostic FPGA Programming
- 2022
-
Ingår i: IEEE 33rd International Conference on Application-specific Systems, Architectures and Processors (ASAP). - 9781665483087 - 9781665483094
-
Konferensbidrag (refereegranskat)abstract
- Current FPGA programming tools require extensive hardware-specific manual code tuning to achieve performance, which is intractable for most software application teams. We present HPVM2FPGA, a novel end-to-end compiler and autotuning system that can automatically tune hardware-agnostic programs for FPGAs. HPVM2FPGA uses a hardware-agnostic abstraction of parallelism as an intermediate representation (IR) to represent hardware-agnostic programs. HPVM2FPGA’s powerful optimization framework uses sophisticated compiler optimizations and design space exploration (DSE) to automatically tune a hardware-agnostic program for a given FPGA. HPVM2FPGA is able to support software programmers by shifting the burden of performing hardware-specific optimizations to the compiler and DSE. We show that HPVM2FPGA can achieve up to 33× speedup compared to unoptimized baselines and can match the performance of hand-tuned HLS code for three of four benchmarks. We have designed HPVM2FPGA to be a modular and extensible framework, and we expect it to match handtuned code for most programs as the system matures with more optimizations. Overall, we believe that it constitutes a solid step closer to fully hardware-agnostic FPGA programming, making it a suitable cornerstone for future FPGA compiler research.
|
|
| 2. |
- Engert, Andreas, et al.
(författare)
-
The European Hematology Association Roadmap for European Hematology Research : a consensus document
- 2016
-
Ingår i: Haematologica. - Pavia, Italy : Ferrata Storti Foundation (Haematologica). - 0390-6078 .- 1592-8721. ; 101:2, s. 115-208
-
Tidskriftsartikel (refereegranskat)abstract
- The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at (sic)23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.
|
|
